Therapeutic outcome of 6198 interferon-naïve Egyptian patients with chronic hepatitis C: a real-life experience and lessons to be learned in DAAs’ era

2016 ◽  
Vol 23 (7) ◽  
pp. 506-511
Author(s):  
N. Zayed ◽  
H. Gamal Eldeen ◽  
H. Elmakhzangy ◽  
M. Seif ◽  
W. El-Akel ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Life Experience ◽  
Real Life ◽  
Therapeutic Outcome ◽  
Egyptian Patients

Direct-acting antiviral agents in the treatment of chronic Hepatitis C – “Real-life” experience from an academic centre and two specialized clinical practices

2017 ◽  
Vol 56 (04) ◽  
pp. 351-360 ◽  
Author(s):  
Manuel Groß ◽  
Georg Härter ◽  
Johanna Backhus ◽  
Eugen Zizer ◽  
Thomas Seufferlein ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Life Experience ◽  
Antiviral Agents ◽  
Real Life ◽  
Clinical Practices ◽  
Genotype 3 ◽  
Svr12 Rate ◽  
Real Life Data

AbstractThe introduction of the new direct antiviral agents has revolutionized the therapy of chronic hepatitis C. Today we are able to cure the vast majority of our patients with an 8- to 12-week therapy course of an antiviral combination therapy with an excellent safety profile. Real-life data are very important to further develop our experience with the new therapeutics and help us to improve the care of our patients in our everyday clinical practice.In our study, we present the retrospective analysis of a representative German cohort of 344 patients with chronic hepatitis C treated with the new direct antiviral agents. The patients were recruited in an academic center of southern Germany (University Clinic of Ulm, Clinic of Internal Medicine I) and in 2 highly specialized clinical practices in the city center and the near region of Ulm. Within this in-detail characterized study cohort, we analyzed the efficacy and safety of antiviral therapy under real-life conditions.In 322 patients, we could document SVR12 data and found an excellent overall SVR12 rate of 97.8 % across all genotypes. In more detail, we could show comparable SVR12 results of 99 % and 99.2 % in patients with the hepatitis C virus subtypes 1a and 1b of and an excellent SVR12 rate of 93.1 % in genotype 3 patients without liver cirrhosis. Nevertheless, SVR12 rates tend to be lower in patients with the presence of liver cirrhosis, especially in genotype 3 patients with the lowest SVR12 rate in the whole study group of only 80 %. In general, there were no major safety issues except of 1 patient treated with a protease-inhibitor-based regimen who developed a generalized skin reaction and needed hospitalization and premature end of antiviral therapy.In summary, our analysis of this well characterized representative cohort of 344 patients adds more information in the field of real-life experience with the new antiviral therapeutics and could therefore contribute to improve the care of our patients. Together with the existing real-life data, we now can proceed in achieving the aim of viral eradication of hepatitis C virus within our population.

Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort

2020 ◽  
Vol 27 (10) ◽  
pp. 964-973
Author(s):  
Victor Lédinghen ◽  
Clovis Lusivika‐Nzinga ◽  
Jean‐Pierre Bronowicki ◽  
Fabien Zoulim ◽  
Dominique Larrey ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Life Experience ◽  
Real Life ◽  
Hepatitis C Infection ◽  
Genotype 2

Real Life Experience in Treating Chronic Hepatitis C with Direct Acting Antivirals: Genotyping and Subtype Matter

2016 ◽  
Vol 64 (2) ◽  
pp. S751-S752
Author(s):  
C. Ramière ◽  
M. Maynard ◽  
K. Hartig-Lavie ◽  
F. Bailly ◽  
V. Virlogeux ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Life Experience ◽  
Real Life ◽  
Direct Acting Antivirals ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document